Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Caladrius Biosciences (CLBS) shares

Learn how to easily invest in Caladrius Biosciences shares.

Caladrius Biosciences is a biotechnology business based in the US. Caladrius Biosciences stocks (CLBS.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.64 – an increase of 7.32% over the previous week. Caladrius Biosciences employs 27 staff and has a market cap (total outstanding stock value) of $25.7 million.

How to buy stocks in Caladrius Biosciences

  1. Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CLBS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Caladrius Biosciences stock price (NASDAQ:CLBS)

Use our graph to track the performance of CLBS stocks over time.

Caladrius Biosciences shares at a glance

Information last updated 2022-05-12.
Latest market close$0.44
52-week range$0.40 - $1.68
50-day moving average $0.66
200-day moving average $0.94
Wall St. target price$8.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.50

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 6 of 6
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
OFFER
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get $500 in commission free trades when you fund your account with a minimum of $10,000. Conditions apply. Ends August 31st, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Caladrius Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Caladrius Biosciences price performance over time

Historical closes compared with the close of $0.44 from 2022-05-13

1 week (2022-05-10) 4.76%
1 month (2022-04-13) -37.14%
3 months (2022-02-17) -42.84%
6 months (2021-11-17) -57.28%
1 year (2021-05-17) -70.47%
2 years (2020-05-15) -75.96%
3 years (2019-05-16) 3.1
5 years (2017-05-16) 5.37

Caladrius Biosciences financials

Gross profit TTM $0
Return on assets TTM -27.3%
Return on equity TTM -44.21%
Profit margin 0%
Book value $1.54
Market capitalisation $25.7 million

TTM: trailing 12 months

Caladrius Biosciences share dividends

We're not expecting Caladrius Biosciences to pay a dividend over the next 12 months.

Have Caladrius Biosciences's shares ever split?

Caladrius Biosciences's shares were split on a 1:10 basis on 27 July 2016. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Caladrius Biosciences shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Caladrius Biosciences shares which in turn could have impacted Caladrius Biosciences's share price.

Caladrius Biosciences share price volatility

Over the last 12 months, Caladrius Biosciences's shares have ranged in value from as little as $0.402 up to $1.68. A popular way to gauge a stock's volatility is its "beta".

CLBS.US volatility(beta: 0.97)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Caladrius Biosciences's is 0.9725. This would suggest that Caladrius Biosciences's shares are less volatile than average (for this exchange).

Caladrius Biosciences overview

Caladrius Biosciences, Inc. , a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc.

Frequently asked questions


Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site